Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

NewsGuard 100/100 Score

Glide Technologies, the development company focused on solid dose formulations of therapeutics and vaccines and non-invasive diagnostics, today announced that its novel solid dose formulation of teriparatide (parathyroid hormone) achieved successful results in a pre-clinical proof-of-concept study comparing it with the currently marketed liquid product (Forteo®/Forsteo®). Based on these results, the company intends to transfer the formulation production process to a contract manufacturing organisation in the coming months, and to advance Glide teriparatide delivered with the company’s needle-free solid dose injector (teriparatide SDI®) into clinical trials in 2016.

The pre-clinical study compared the pharmacokinetic profile of the most widely used clinical dose of teriparatide (20 mcg) with that of Glide’s solid dose formulation delivered using the company’s SDI®. The results demonstrated that there was no statistical difference between the two profiles (p<0.05). Teriparatide is currently approved for use in the treatment of osteoporosis with 2014 sales in excess of $1.3 billion.

Dr Mark Carnegie-Brown, Glide’s CEO, commented:

These results follow positive equivalence data with octreotide SDI®, and demonstrate the flexibility of the Glide SDI® platform in delivering therapeutic peptides. We believe that the Glide SDI® will have particular advantages with self-administered treatments, such as teriparatide and octreotide, and we are expanding our pipeline to encompass additional therapeutic areas where patient-focused products are key, such as diabetes.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Scientists discover how oxytocin influences memory in animals